Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study

Henri J.M.M. Mutsaerts,1,* Saira S. Mirza,1,* Jan Petr,2 David L. Thomas,3 David M. Cash,3 Martina Bocchetta,3 Enrico de Vita,3 Arron W.S. Metcalfe,1 Zahra Shirzadi,1 Andrew D. Robertson,1 Maria Carmela Tartaglia,4,5,6 Sara B. Mitchell,1,6,7 Sandra E. Black,1,6,7 Morris Freedman,6,8 David Tang-Wai,5,6 Ron Keren,5 Ekaterina Rogaeva,4 John van Swieten,9 Robert Laforce Jr,10 Fabrizio Tagliavini,11 Barbara Borroni,12 Daniela Galimberti,13 James B. Rowe,14 Caroline Graff,15 Giovanni B. Frisoni,16 Elizabeth Finger,17 Sandro Sorbi,18 Alexandre de Mendonça,19 Jonathan D. Rohrer,3 Bradley J. MacIntosh1 and Mario Masellis1,6,7,20 on behalf of the GENetic Frontotemporal dementia Initiative (GENFI)†

*These authors contributed equally to this work.
†Appendix 1.

Genetic forms of frontotemporal dementia are most commonly due to mutations in three genes, C9orf72, GRN or MAPT, with presymptomatic carriers from families representing those at risk. While cerebral blood flow shows differences between frontotemporal dementia and other forms of dementia, there is limited evidence of its utility in presymptomatic stages of frontotemporal dementia. This study aimed to delineate the cerebral blood flow signature of presymptomatic, genetic frontotemporal dementia using a voxel-based approach. In the multicentre GENetic Frontotemporal dementia Initiative (GENFI) study, we investigated cross-sectional differences in arterial spin labelling MRI-based cerebral blood flow between presymptomatic C9orf72, GRN or MAPT mutation carriers (n = 107) and non-carriers (n = 113), using general linear mixed-effects models and voxel-based analyses. Cerebral blood flow within regions of interest derived from this model was then explored to identify differences between individual gene carrier groups and to estimate a timeframe for the expression of these differences. The voxel-based analysis revealed a significant inverse association between cerebral blood flow and the expected age of symptom onset in carriers, but not non-carriers. Regions included the bilateral insulae/orbitofrontal cortices, anterior cingulate/paracingulate gyri, and inferior parietal cortices, as well as the left middle temporal gyrus. For all bilateral regions, associations were greater on the right side. After correction for partial volume effects in a region of interest analysis, the results were found to be largely driven by the C9orf72 genetic subgroup. These cerebral blood flow differences first appeared approximately 12.5 years before the expected symptom onset determined on an individual basis. Cerebral blood flow was lower in presymptomatic mutation carriers closer to and beyond their expected age of symptom onset in key frontotemporal dementia signature regions. These results suggest that arterial spin labelling MRI may be a promising non-invasive imaging biomarker for the presymptomatic stages of genetic frontotemporal dementia.

1 Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, Canada
2 PET Center, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
3 Institute of Neurology, University College London, London, UK
4 Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
Brain perfusion in frontotemporal dementia

Introduction

Frontotemporal dementia encompasses a pathologically heterogeneous group of neurodegenerative diseases, characterized clinically by prominent behavioural and/or language disruption. Frontotemporal dementia significantly impacts patients and their families during the prime of their lives when individuals have responsibilities to their careers, raising children and social interactions (Neary et al., 2005; Onyike and Diehl-Schmid, 2013). It is highly heritable, with an autosomal dominant family history documented in about one-third of people with the disease (Rohrer et al., 2013). The study of presymptomatic mutation carriers compared to non-carriers affords a unique opportunity to understand more about the natural history of genetic frontotemporal dementia during the preclinical phases.

One priority in frontotemporal dementia research is to develop imaging biomarkers (Neary et al., 2005; Rohrer et al., 2013). It is hoped that such biomarkers of genetic frontotemporal dementia could identify those at highest risk of transitioning into the clinical phase, the clinical subtype that will develop, and the age when symptoms will appear. Furthermore, these biomarkers may allow for longitudinal monitoring of disease progression, as well as evaluating efficacy of potential disease-modifying drugs (Cenik et al., 2011; Bateman et al., 2012). Indeed, brain changes have been demonstrated with imaging in presymptomatic/early stage genetic Alzheimer’s disease (Bateman et al., 2012). Our structural MRI work on presymptomatic/early stage genetic frontotemporal dementia, as well as that of others, has previously shown early brain changes, particularly in the fronto-insular-temporal regions (Rohrer et al., 2015; Lee et al., 2017; Bertrand et al., 2018). A potential functional imaging biomarker is arterial spin labelling (ASL) perfusion MRI. Increasing evidence suggests that perfusion changes in frontotemporal dementia may be more extensive than structural brain changes early on in the disease course (Olm et al., 2016). ASL allows non-invasive imaging of cerebral blood flow in vivo (Alsop et al., 2015). In contrast to other perfusion imaging techniques, ASL uses blood water as an endogenous tracer, which is safe and ideal for longitudinal imaging (Alsop et al., 2015).

Several studies have shown that ASL cerebral blood flow can distinguish symptomatic frontotemporal dementia cases from controls and other dementias (Hu et al., 2010; Shimizu et al., 2010; Binnewijzend et al., 2014; Olm et al., 2016; Steketee et al., 2016). To our knowledge, only one study conducted at a single site has examined the use of ASL perfusion MRI in contrasting presymptomatic MAPT and GRN mutation carriers (n = 34 combined) to non-carriers (n = 31) (Dopper et al., 2016). Whilst they did not find any cross-sectional differences in perfusion between carriers and non-carriers at baseline, they demonstrated a significant reduction in perfusion of the frontal pole, superior frontal gyrus, paracingulate gyrus, posterior (mid)cingulate gyrus, precuneus, and thalamus among GRN carriers compared to non-carriers on 2...
Materials and methods

Participants

Data were drawn from the second data freeze of GENFI (Rohrer et al., 2015), which consisted of centres in the UK, Italy, The Netherlands, Sweden, Portugal and Canada. GENFI participants included known symptomatic carriers of a pathogenic mutation in C9orf72, GRN or MAPT and their first-degree relatives who were at risk of carrying a mutation, but who did not show any symptoms (that is, presymptomatic). Non-carriers were first-degree relatives of symptomatic carriers who did not carry the mutation. The inclusion and exclusion criteria are described in detail elsewhere (Rohrer et al., 2015). As part of the standard GENFI protocol, subjects and a close contact of them were interviewed by a neurologist using a checklist of symptoms relating to frontotemporal dementia. Symptoms were rated as absent, questionable/very mild, mild, moderate or severe in nature and ratings were corroborated by both the patient and their close contact. Presymptomatic individuals scored for the most part as having symptoms absent and, on occasion, in the very mild/questionable range. They also could not have any cognitive, behavioural or language deficits that resulted in a functional decline in terms of both their basic and/or instrumental activities of daily living. Ethical review boards from participating centres approved the GENFI protocol and all participants provided written informed consent according to the Declaration of Helsinki. Data were collected between January 2012 and March 2015 at nine GENFI sites and based on acquiring 3T ASL and T1-weighted MRI images in 294 participants. Symptomatic carriers (32 individuals) were excluded from the primary analysis (see statistical analysis section below) since the focus of this study was on the presymptomatic stage. However, as outlined below, perfusion data from symptomatic carriers were included in a secondary analysis. Our semi-automatic quality control procedure (outlined below) excluded 42 scans due to motion and other artefacts. Data from 220 presymptomatic participants were included in the primary analysis (Table 1 and Supplementary Fig. 1).

Table 1 Descriptive characteristics (n = 220)

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Non-carriers (n = 113, 51.4%)</th>
<th>Presymptomatic mutation carriers (n = 107, 48.6%)</th>
<th>Test statistic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>50.1 ± 14.3</td>
<td>46.1 ± 11.5</td>
<td>t(218) = 2.24, P = 0.03</td>
</tr>
<tr>
<td>Sex (male)</td>
<td>41 (36.3%)</td>
<td>41 (38.3%)</td>
<td>χ²(1) = 0.09, P = 0.76</td>
</tr>
<tr>
<td>Handedness (right dominant)</td>
<td>103 (91.2%)</td>
<td>96 (89.7%)</td>
<td>χ²(1) = 0.13, P = 0.72</td>
</tr>
<tr>
<td>Education (years)</td>
<td>14.1 ± 3.1</td>
<td>14.2 ± 3.0</td>
<td>t(218) = 0.22, P = 0.83</td>
</tr>
<tr>
<td>Average years from expected symptom onset</td>
<td>−9.3 ± 14.4</td>
<td>−11.0 ± 11.8</td>
<td>t(218) = 0.92, P = 0.36</td>
</tr>
<tr>
<td>Carrier status based on genetic subgroup</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C9orf72</td>
<td>34 (30.1%)</td>
<td>34 (31.8%)</td>
<td>χ²(1) = 0.07, P = 0.79</td>
</tr>
<tr>
<td>GRN</td>
<td>68 (60.2%)</td>
<td>55 (51.4%)</td>
<td>χ²(1) = 1.72, P = 0.19</td>
</tr>
<tr>
<td>MAPT</td>
<td>11 (9.7%)</td>
<td>18 (16.8%)</td>
<td>χ²(1) = 2.41, P = 0.12</td>
</tr>
<tr>
<td>Cognitive and behavioural measures</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mini-Mental State Examination (/30)</td>
<td>29.2 ± 1.1</td>
<td>29.1 ± 1.4</td>
<td>t(197) = 0.91, P = 0.36</td>
</tr>
<tr>
<td>Cambridge Behavioural Inventory-Revised (/180)</td>
<td>3.9 ± 5.7</td>
<td>4.8 ± 10.1</td>
<td>t(193) = 0.74, P = 0.46</td>
</tr>
<tr>
<td>Frontotemporal Dementia Rating Scale (categories)*</td>
<td>0 (IQR 0–0)</td>
<td>0 (IQR 0–0)</td>
<td></td>
</tr>
</tbody>
</table>

Data are n (%) or mean ± standard deviation. Statistics for differences between non-carriers and presymptomatic mutation carriers are shown in the fourth column. IQR = interquartile range.

*Frontotemporal Dementia Rating Scale categories = 0 (very mild), 1 (mild), 2 (moderate), 3 (severe), 4 (very severe), and 5 (profound); this scale was designed to be used in symptomatic subjects and so there is a floor effect when applied to presymptomatic subjects leading them to be classified in the very mild range even though they do not have significant functional involvement.
Mutation testing

DNA extraction took place at local sites according to their standard procedures. Mutation testing of participants also took place at local sites either through direct DNA sequencing or allele-specific PCR-based screening of GRN or MAPT. C9orf72 hexanucleotide repeat expansions were evaluated using a two-step genotyping procedure as previously described (Dejesus-Hernandez et al., 2011). A pathogenic expansion of C9orf72 was considered as having more than 30 repeats.

Image acquisition

T1-weighted and ASL acquisition sequences were harmonized across scanners from different sites, as best as possible (Rohrer et al., 2015). The product ASL sequences are fundamentally different between vendors, thus we opted for four implementations to achieve best results: pseudo-continuous ASL (PCASL) 3D fast-spin-echo stack-of-spirals implemented on a 3 T General Electric MR750 (one site, n = 22); PCASL 2D gradient-echo-planar imaging (EPI) on a 3 T Philips Achieva, with (one site, n = 99) and without (two sites, n = 32) background suppression; and a pulsed ASL 3D gradient-and-spin-echo (GRASE) on 3 T Siemens Trio systems (five sites, n = 67). ASL parameters are described elsewhere (Mutsaerts et al., 2018).

ASL image processing

We used ExploreASL to process the multicentre ASL data (Mutsaerts et al., 2015), a toolbox based on Matlab (MathWorks, MA, USA), Statistical Parametric Mapping 12 (SPM12, Wellcome Trust Centre for Neuroimaging, University College London, UK) and Diffeomorphic Anatomical Registration analysis using Exponentiated Lie algebra (DARTEL) (Ashburner, 2007).

GENFI ASL image processing was optimized to process data from multiple sites, vendors and sequences (Mutsaerts et al., 2015). The product ASL sequences are fundamentally different between vendors, thus we opted for four implementations to achieve best results: pseudo-continuous ASL (PCASL) 3D fast-spin-echo stack-of-spirals implemented on a 3 T General Electric MR750 (one site, n = 22); PCASL 2D gradient-echo-planar imaging (EPI) on a 3 T Philips Achieva, with (one site, n = 99) and without (two sites, n = 32) background suppression; and a pulsed ASL 3D gradient-and-spin-echo (GRASE) on 3 T Siemens Trio systems (five sites, n = 67). ASL parameters are described elsewhere (Mutsaerts et al., 2018).

ASL quality control

For inclusion of scans, a novel semi-automatic quality control method was used (Supplementary Fig. 2). This method ranks scans by their spatial coefficient of variation (CoV) (Mutsaerts et al., 2017), which reflects the amount of arterial transit time artefacts. After excluding the worst quality scans (unsuitable) by visual assessment, all remaining scans were categorized into: (i) ‘good’ (CoV ≤ 0.6, cerebral blood flow signal predominates

![Figure 1](https://academic.oup.com/brain/article-abstract/142/4/1108/5371511/1111)
artefacts); (ii) ‘acceptable’ (0.6 \( \leq \) CoV \( \leq \) 0.8, both cerebral blood flow signal and artefacts visible); or (iii) ‘bad’ (CoV > 0.8, artefacts predominate cerebral blood flow signal). Three authors (Z.S., A.D.R. and H.J.M.M.M.), each with 3–6 years of experience in handling ASL data, independently reviewed and corrected the CoV-based categorization of the images. Inconsistencies were resolved by consensus. Only the 220 ‘good’ scans were included in the primary analyses (Supplementary Fig. 2).

To adjust for site differences, we performed a spatially varying intensity normalization, which uses the within-site cerebral blood flow similarity between participants to remove the between-site quantification differences. To facilitate this intensity normalization, scanners that contributed 5 artefact-free scans were excluded in the quality control step (nine scans in total). Residual site effects were minimized by spatial intensity normalization using site-specific bias-fields, as follows: (i) a mean cerebral blood flow image was created for each site; (ii) this image was smoothed with a 6.4 mm full-width at half-maximum (FWHM) Gaussian kernel, constrained by a Montreal Neurological Institute (MNI) brain mask; (iii) these site-specific smoothed mean cerebral blood flow images were averaged to create a population-average cerebral blood flow image, which was rescaled to a mean grey matter cerebral blood flow of 60 ml/100 g/min; (iv) site-specific bias-fields were created by dividing the population-average cerebral blood flow image with the site-specific cerebral blood flow images; and (v) individual cerebral blood flow images were multiplied by site-specific bias field maps.

The voxel-based analysis was restricted to voxels that had both adequate ASL signal-to-noise ratio (Viviani et al., 2009) and were segmented as grey matter with probability \( > 20\% \).

**Statistical analysis**

We compared demographic and clinical characteristics between presymptomatic mutation carriers and non-carriers using \( t \)-tests for continuous and chi-square tests for categorical variables. In our primary analyses, we used linear mixed-effects models to test for cerebral blood flow differences between presymptomatic non-carriers and mutation carriers in voxel-based and regional analyses. This model accounted for fixed and random effects of predictor variables, including intercept terms (Sullivan et al., 1999; Rohrer et al., 2015; Masellis et al., 2016). The fixed effect predictor variables of interest were mutation carrier status, years to age of expected symptom onset, and the interaction between mutation carrier status and years to age of expected symptom onset. Years to age of expected symptom onset was calculated from the mean age at onset in symptomatic family members—e.g. someone aged 50 years at the time of assessment with a mean age at symptom onset of 55 years in their family would have a years to age of expected symptom onset of –5 years (Rohrer et al., 2015). Family membership was included in the model as a random effect, as it was expected that members from the same family might have covariance in brain perfusion due to a shared genetic and environmental background (Rohrer et al., 2015). Sex and site were also added as fixed effect covariates. Age was included as a covariate in a preliminary model but was removed through a model building step because it was captured almost entirely by the years to age of expected symptom onset variable. In a sensitivity analysis, the described model was also run replacing years to age of expected symptom onset with age. The covariance matrix of family relatedness,
Brain perfusion in frontotemporal dementia

Results

Demographic, cognitive and behavioural measures and family distribution across sites

Apart from mutation carriers being younger than non-carriers, no significant differences in demographic, general cognitive and behavioural measures were observed between the two groups (Table 1). Supplementary Fig. 1 provides an overview of the family distribution across the different sites for all participants. Site and family membership were strongly related, but nonetheless were considered as covariates due to the importance of both of these factors.

Timing of cerebral blood flow decline

Instead of stratifying years to age of expected symptom onset at regular time points, e.g. 5– or 10-year intervals, we used a quantile approach to account for the high physiological cerebral blood flow variability on an individual basis by ensuring equal numbers of participants per time interval. Subsequently, the association between quantiles of years to age of expected symptom onset and cerebral blood flow was tested using linear mixed models, adjusting for sex and site (fixed effects), and family (random effects) as covariates in presymptomatic non-carriers and carriers separately. In these models, the quantile variable was used as a categorical predictor variable with the first quantile as the reference quantile. We tested quintiles, sextiles, septiles, octiles, and deciles to ensure robustness of results. Since octiles enabled us to explore smaller intervals with a reasonable number of participants per interval to obtain valid estimates, we present results for octiles only.

Secondary analysis comparing symptomatic and presymptomatic mutation carriers

To understand the perfusion data further, we compared cerebral blood flow in mutation carriers who were symptomatic (n = 31) to those who remained presymptomatic past their expected age of symptom onset (n = 23). This was done using t-tests and linear regression models adjusted for age and sex of participants. This analysis used cerebral blood flow that was extracted from within the voxel-based defined regions of interest as described previously. As we were interested in comparing cerebral blood flow in symptomatic versus presymptomatic carriers who were beyond their expected age of symptom onset, we excluded all non-carriers, presymptomatic carriers who did not meet this criterion, and one symptomatic mutation carrier who had a very high cerebral blood flow value in the left supramarginal/angular gyri, thus considered an outlier.

Partial volume correction

We implemented a partial volume correction to mitigate any regional tissue differences that would act as a confound (Asllani et al., 2008). Region of interest analyses were performed with and without the partial volume correction. Since the regions of interest were derived from the voxel-based analysis, which was restricted to the grey matter, they were dilated centrally to include sufficient white matter voxels for a robust partial volume correction. Specifically, the region of interest was eroded in volume until the white matter voxels accounted for <50% of the total volume. As a result of differences in effective resolution and smoothness between ASL sites (Mutsaerts et al., 2018), we estimated the effective spatial resolution based on the different ASL implementations (Vidorreta et al., 2013; Mutsaerts et al., 2018), which could contribute to partial volume error. We assumed the following effective resolutions in FWHM: 3.7 x 3.7 x 7.6 mm (2D EPI with background suppression), 4.6 x 4.6 x 4.3 mm (2D EPI without background suppression), 3.75 x 3.75 x 5.5 mm (3D GRASE) (Vidorreta et al., 2013), 5.0 x 5.0 x 9.5 mm (3D spiral),

Voxel-based analysis and subsequent derivation of regions of interest

The regions where cerebral blood flow was significantly different between presymptomatic carriers and non-carriers were identified from the voxel-based analysis. Images were smoothed, constrained by the voxel-based mask, with a 3.4 mm FWHM Gaussian kernel (Dopper et al., 2016). The primary cluster-forming threshold was P = 0.005, with the extent threshold set at P = 0.05 for family-wise error (FWE) correction. Regions of lower perfusion identified in the voxel-based analysis in presymptomatic carriers compared to non-carriers based on their years to age of expected symptom onset were named according to their overlap with the Harvard-Oxford atlas (Desikan et al., 2006). These voxel-based identified areas defined our regions of interest. Median grey matter cerebral blood flow was extracted from each region of interest for subsequent regional analyses within the overall group, as well as stratified between genetic subgroups. The region of interest analyses evaluated whether there were differences in the associations linking extracted cerebral blood flow with years to age of expected symptom onset between presymptomatic carriers and non-carriers using linear mixed models, taking into account fixed effects of sex and site, and random effects of family membership as covariates. To test if there were non-linear changes in cerebral blood flow, we also tested a quadratic term for years to age of expected symptom onset. Sensitivity analyses were performed by repeating the analysis with age replacing years to age of expected symptom onset and after a high-only winsorization of 0 to 10 values of cerebral blood flow to account for cerebral blood flow outliers.

Data availability

Data will be shared according to the GENFI data sharing agreement, after review by the GENFI data access committee with final approval granted by the GENFI steering committee.
Voxel-based analysis

Years to age of expected symptom onset predicted a lower cerebral blood flow due to decline in perfusion with age. While no main effect of carrier status on cerebral blood flow was observed, we identified a robust and statistically significant carrier status × years to age of expected symptom onset interaction. Specifically, as shown by Table 2 and Fig. 1, we identified several regions with a significantly greater inverse association between cerebral blood flow and the expected age of symptom onset in presymptomatic mutation carriers compared to non-carriers. Six regions were identified by the voxel-based analysis including: the left middle temporal gyrus, bilateral anterior cingulate/paracingulate gyri, bilateral anterior insula/orbitofrontal gyri, and bilateral supramarginal/angular gyri. The peak t-statistics were higher for clusters in the right hemisphere compared to the left hemisphere for the anterior insula/orbitofrontal gyri (t = 5.2 versus t = 4.8), supramarginal/angular gyri (t = 5.8 versus t = 4.6) and for the anterior cingulate/paracingulate cortex (t = 4.6 versus t = 3.9).

Regions of interest analysis

Table 3 shows the difference in association of cerebral blood flow with years to age of expected symptom onset between presymptomatic carriers and non-carriers within the voxel-based analysis-defined regions of interest in the overall group and stratified for genetic subgroup, with and without partial volume correction. The main effect of years to age of expected symptom onset and the interaction effect of years to age of expected symptom onset × carrier status were significantly associated with cerebral blood flow in all regions of interest, with the exception of the right supramarginal/angular gyri wherein only the interaction term was significant. These results were consistent before and after partial volume correction in the entire cohort. In analyses without partial volume correction applied, all genetic subgroups contributed to the main effect of years to age of expected symptom onset. However, after partial volume correction was applied, results seemed to be largely driven by the C9orf72 group. The interaction between years to age of expected symptom onset and carrier status was only found in the C9orf72 group after applying partial volume correction.

The quadratic term for years to expected age of symptom onset was not significant and did not improve the model fit, therefore, it was not included in the model. In a sensitivity analysis, when years to age of expected symptom onset was replaced by age, the same clusters survived, albeit to a lesser extent. The regional analysis was also repeated with age instead of years to age of expected symptom onset and after high-only winsorization of zero to 10 values to account for cerebral blood flow outliers, which did not change the results.

Estimation of time of cerebral blood flow decline

In the analyses of octiles of years to age of expected symptom onset and cerebral blood flow in the entire cohort, we observed that cerebral blood flow in carriers started to differ significantly from the fourth octile onward (corresponding to −14.8 to −9.3 years) compared to the first octile, which was used as a reference (−40.9 to −25.1 years). This means that on average, the change in cerebral blood flow in presymptomatic carriers starts to occur at ~12.5 years before their expected years to age of symptom onset. This pattern was observed for all regions of interest (Supplementary Tables 1 and 2) in presymptomatic mutation carriers only. No differences in cerebral blood flow between the octiles were observed in non-carriers (Supplementary Tables 1 and 2, and Fig. 2). Figure 2 represents cerebral blood flow decline in presymptomatic carriers and non-carriers over years to age of expected symptom onset in each of the identified voxel-based analysis-defined regions of interest. Carriers who were several years away from their age of predicted symptom onset had higher cerebral blood flow values than non-carriers with similar years to age of expected symptom onset. In contrast, carriers who were beyond their age of expected symptom onset had lower cerebral blood flow values than non-carriers with similar years to age of expected symptom onset. This resulted in a steeper negative slope of the regression lines for each region of interest in carriers than in non-carriers.
Table 3 Region of interest analysis comparing cerebral blood flow between carriers and non-carriers modelled based on years to age of expected symptom onset and its interaction with carrier status

<table>
<thead>
<tr>
<th>VBA-derived regions of interest</th>
<th>All carriers (n = 107) versus non-carriers (n = 113)</th>
<th>C9orf72 carriers (n = 34) versus non-carriers (n = 113)</th>
<th>GRN carriers (n = 55) versus non-carriers (n = 113)</th>
<th>MAPT carriers (n = 118) versus non-carriers (n = 113)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β</td>
<td>Cl</td>
<td>P</td>
<td>β</td>
</tr>
<tr>
<td><strong>Regions of interest without partial volume correction</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L middle temporal gyrus</td>
<td>−0.20 (−0.32, −0.09)</td>
<td>0.001 &lt; 0.001</td>
<td>−0.15 (−0.27, −0.02)</td>
<td>0.026</td>
</tr>
<tr>
<td>B anterior cingulate/paracingulate gyrri</td>
<td>−0.38 (−0.53, −0.23)</td>
<td>&lt; 0.001</td>
<td>−0.29 (−0.46, −0.12)</td>
<td>0.001</td>
</tr>
<tr>
<td>R anterior insula, orbitofrontal gyrri</td>
<td>−0.35 (−0.50, −0.20)</td>
<td>&lt; 0.001</td>
<td>−0.28 (−0.45, −0.11)</td>
<td>0.001</td>
</tr>
<tr>
<td>L anterior insula, orbitofrontal gyrri</td>
<td>−0.35 (−0.49, −0.21)</td>
<td>&lt; 0.001</td>
<td>−0.32 (−0.49, −0.16)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>R supramarginal/angular gyrri</td>
<td>−0.06 (−0.21, 0.08)</td>
<td>0.379 &lt; 0.001</td>
<td>0.05 (−0.11, 0.20)</td>
<td>0.547</td>
</tr>
<tr>
<td>L supramarginal/angular gyrri</td>
<td>−0.20 (−0.33, −0.06)</td>
<td>0.004 &lt; 0.001</td>
<td>−0.14 (−0.29, 0.01)</td>
<td>0.072</td>
</tr>
<tr>
<td><strong>Regions of interest with partial volume correction</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L middle temporal gyrus</td>
<td>−0.16 (−0.27, −0.05)</td>
<td>0.005 0.007</td>
<td>−0.15 (−0.28, −0.02)</td>
<td>0.026</td>
</tr>
<tr>
<td>B anterior cingulate/paracingulate gyrri</td>
<td>−0.15 (−0.28, −0.01)</td>
<td>0.008</td>
<td>−0.10 (−0.26, −0.05)</td>
<td>0.205</td>
</tr>
<tr>
<td>R anterior insula, orbitofrontal gyrri</td>
<td>−0.20 (−0.33, −0.07)</td>
<td>0.003</td>
<td>−0.15 (−0.31, 0.005)</td>
<td>0.057</td>
</tr>
<tr>
<td>L anterior insula, orbitofrontal gyrri</td>
<td>−0.18 (−0.31, −0.05)</td>
<td>0.007</td>
<td>−0.16 (−0.31, −0.004)</td>
<td>0.045</td>
</tr>
<tr>
<td>R supramarginal/angular gyrri</td>
<td>−0.02 (−0.15, 0.12)</td>
<td>0.809</td>
<td>0.01 (−0.15, 0.18)</td>
<td>0.876</td>
</tr>
<tr>
<td>L supramarginal/angular gyrri</td>
<td>−0.07 (−0.20, 0.07)</td>
<td>0.336</td>
<td>0.001 (−0.19, −0.03)</td>
<td>0.728</td>
</tr>
</tbody>
</table>

Cerebral blood flow difference in carriers versus non-carriers in association with years to age of expected symptom onset. (l, 95% confidence interval, P-value, and P-value of interaction between carrier-status and years to age of expected symptom onset).

Regions of interest from the voxel-based analysis (VBA) were derived, and were used for mixed effects models with and without partial volume error correction (Asllani et al., 2008). Estimates represent difference in cerebral blood flow between carriers and non-carriers and were adjusted for sex (fixed) and family relatedness (random). P represents P-values for the association between cerebral blood flow and years to age of expected symptom onset, and Pint represents the P-value for interaction between gene carrier-status and years to age of expected symptom onset on cerebral blood flow in the particular group. B = bilateral; L = left; R = right.
non-carriers, which remained consistent after we repeated our analyses with mean-centred cerebral blood flow values. A similar pattern of results was observed across all regions of interest.

Secondary analysis comparing symptomatic and presymptomatic mutation carriers

While mean cerebral blood flow values were always lower in symptomatic carriers (demographic characteristics in Supplementary Table 3) than in presymptomatic carriers who were beyond their expected age of symptom onset (Supplementary Table 4), this association only reached statistical significance in the bilateral cingulate and insulae/orbitofrontal gyri, as well as the left supramarginal/angular gyri. Linear regression models also showed similar results after adjusting for age and sex (Supplementary Table 5).

Discussion

This multicentre GENFI ASL perfusion study has identified frontal, temporal and parietal brain regions where cerebral blood flow is altered among presymptomatic frontotemporal dementia mutation carriers compared to non-carrier family members. We found some evidence of a laterality effect, whereby the right hemisphere appeared to be more affected than the left hemisphere in the frontoparietal regions. The specific brain regions detected include: the medial frontal cortex, specifically the bilateral anterior cingulate and paracingulate gyri; the orbitofronto-insular cortex bilaterally; the inferior parietal region, specifically the bilateral supramarginal/angular gyri; and the left middle temporal gyrus. Our important and novel findings are highlighted by the following. First, presymptomatic mutation carriers were slightly younger than non-carriers, further strengthening the premise that the mutations, in combination with expected age at symptom onset, had a greater impact on cerebral perfusion than age alone. Second, adjusting for potential atrophy effects through partial volume correction did not influence the gene carrier to cerebral blood flow associations, but nonetheless seemed to implicate a stronger cerebral blood flow influence for the C9orf72 carriers compared to the GRN and MAPT gene carrier subgroups. Third, the lower regional cerebral blood flow in presymptomatic mutation carriers based on age from estimated time of symptom onset occurred approximately 12.5 years before the average age of onset of symptoms in affected family members, albeit from a higher baseline level of cerebral blood flow. In presymptomatic carriers compared to non-carriers, the slight increase in cerebral blood flow seen between octile -9.1 to -4.7 years may represent a rebound phenomenon. It is conceivable that in order to preserve behaviour, cognition and function as an individual approaches their expected age of symptom onset, there may be a compensatory rise in cerebral blood flow before it becomes more severely deficient. Alternatively, this may simply be the result of natural variation in cerebral blood flow and an artefact of the cross-sectional analysis performed here. This phenomenon will be explored in more detail in future longitudinal analyses correlating it with changes in behavioural and cognitive performance. Fourth, in a secondary analysis, presymptomatic carriers who were beyond their expected age of symptom onset had relatively higher regional cerebral blood flow than symptomatic carriers indicating the potential protective effects of preserved cerebral blood flow with respect to delaying symptom onset.

These findings demonstrate the potential utility of non-invasive perfusion MRI as an early imaging biomarker for genetic forms of frontotemporal dementia during the presymptomatic phase. The medial frontal and orbitofronto-insular regions of hypoperfusion identified as presymptomatic carriers approached their expected age of symptom onset in this study overlap with regions of atrophy identified in our previous neuroanatomical study (Cash et al., 2018). These regions are part of a distributed network previously shown to be involved in aberrant socio-emotional processing observed in frontotemporal dementia. Specifically, the anterior insula is a critical hub region that, together with the dorsal anterior cingulate cortex, form part of the salience network and the paralimbic system involved in cognitive, sensory and affective regulation (Menon, 2015). The orbitofrontal cortex receives limbic projections from the cingulate and parahippocampal cortices, hippocampus and amygdala and also receives innervation from all the sensory modalities, thus integrating sensory, memory and emotional information (Viskontas et al., 2007). Anatomically, it transitions into the insula via the frontoinsular cortex, which is an agranular region that contains von Economo neurons (Seeley, 2010). This neuronal cell type is also present in the anterior cingulate cortex further strengthening the cytoarchitectonic link between these two cortical regions (Seeley, 2010).

Accumulating evidence indicates that von Economo neurons may be most susceptible early on to neuropathological and degenerative processes involved in frontotemporal dementia (Seeley et al., 2006), leading some to posit that this cell type is responsible for the early regional vulnerability of the anterior cingulate and insular cortices (Seeley et al., 2007). With respect to clinical phenotype, behavioural variant frontotemporal dementia is nearly four times as common as presentations with primary progressive aphasia (Hogan et al., 2016). The reason for this observation is not known, but the rightward, regional frontal involvement seen in the current study overlaps with findings in studies of symptomatic frontotemporal dementia. Specifically, prior imaging (Miller et al., 1993; Mychack et al., 2001; Schroeter et al., 2007; Gordon et al., 2016) and pathological case series (Irwin et al., 2018) have shown regional involvement of the anterior cingulate/paracingulate, orbitofrontal and/or anterior insular cortices with a right
hemispheric predilection for behavioural variant frontotemporal dementia. Based on our findings in the context of existing literature, we anticipate that the majority of our presymptomatic cohort would be predisposed to develop behavioural variant frontotemporal dementia, which is the subject of future study using longitudinal GENFI data. If the theory of vulnerability via von Economo neurons in early stage frontotemporal dementia is correct, then the right-predominant hemispheric involvement in frontotemporal dementia may be related to the higher number of susceptible von Economo neurons in the right anterior insula and anterior cingulate cortex than on the left in post-natal brains (Allman et al., 2011).

Hypoperfusion was also seen in the left middle temporal gyrus in presymptomatic carriers in relation to their expected age of symptom onset. The posterior aspect of this structure is strongly connected to the left inferior frontal gyrus, and together they contribute to controlled semantic retrieval (Davey et al., 2015). A quantitative meta-analysis has revealed that the semantic variant of primary progressive aphasia is associated with grey matter atrophy involving the bilateral inferior temporal and fusiform gyri, the medial aspect of the temporal lobes (including parahippocampal gyri and amygdala), as well as the left temporal pole, middle temporal gyrus, and caudate (Yang et al., 2012). Whether or not presymptomatic mutation carriers who have prominent hypoperfusion involving the left middle temporal gyrus will go on to develop clinical features of semantic dementia will have to be determined through longitudinal monitoring of the GENFI cohort.

The inferior parietal lobule bilaterally showed lower perfusion in presymptomatic carriers compared to non-carriers in association with their expected age at symptom onset. This structure is made up of the supramarginal (rostral portion) and angular (caudal portion) gyri, and through connections with frontal, temporal and occipital cortex, it is important for sensorimotor integration (Caspers et al., 2013). In the left hemisphere, the inferior parietal lobule is part of the dorsal stream for auditory perception playing a role in verbal working memory, phonological short-term memory, and temporal ordering of articulation and sound (Binkofski et al., 2016). It is also involved in motor functions and interactions with objects (Binkofski et al., 2016). The left angular gyrus is involved in reading, writing, verbal repetition, naming, processing of semantic content and contributes to modality-independent conceptual and semantic processes linking language and action networks (Binkofski et al., 2016). In the right hemisphere, the rostral and middle inferior parietal lobule is involved in spatial coding and attention, as well as learning and execution of complex sequential motor movements, including those involved in multi-tool/object use (Binkofski et al., 2016).

Bilaterally, the rostral inferior parietal lobule forms part of the ventrodorsal stream of visual perception involved in sensorimotor information processing based on object use representations; lesions to this structure can impair both pantomime and real object use resulting in limb apraxia (Binkofski et al., 2016). On the right side, the angular gyrus is involved in spatial functions with lesions of this structure producing hemi-neglect (Binkofski et al., 2016). There is evidence of atrophy, reduced functional connectivity and perfusion, and pathological involvement of the inferior parietal lobule that correlates with disturbances in language and praxis observed in GRN-related frontotemporal dementia (Rohrer et al., 2010; Seelaar et al., 2011a; Premi et al., 2014; Kim et al., 2016). Therefore, it is possible that the presymptomatic GRN carriers in this study might be driving our observed cerebral blood flow association with the inferior parietal lobule, although we did not have the power to assess this directly.

Interestingly, as illustrated in Fig. 2, presymptomatic mutation carriers tended on average to have higher perfusion than non-carriers several years before their predicted age of symptom onset, but carriers who were beyond their predicted age of symptom onset tended to have lower perfusion than their non-carrier counterparts in the same time period. This raises the possibility that compensatory mechanisms involving cerebral perfusion may be at work early during the presymptomatic phase in mutation carriers to maintain normal brain functions. Compensatory mechanisms have been hypothesized to be at play in young APOE ε4 allele carriers at risk for Alzheimer’s disease using both resting state and task-based functional MRI demonstrating increased default mode network connectivity at rest and during an encoding task compared to their non-carrier counterparts (Filippini et al., 2009). However, a more recent ASL perfusion MRI study in cognitively normal older adults carrying the APOE ε4 allele demonstrated increased perfusion involving the medial frontal cortex, medial and lateral temporal cortex, parietal regions, insula, and the basal ganglia that was associated with worse verbal memory functions (Zlatar et al., 2016). Other than the use of different functional imaging modalities, it is possible that the conflicting observations might be due to differences in the age of the participants included in the two studies. For example, compensatory mechanisms may start to break down in older APOE ε4 participants due to increasing age as Alzheimer’s brain pathological burden becomes more prominent and we hypothesize a similar process may be seen in autosomal dominant frontotemporal dementia. Data presented in Fig. 2 and Supplementary Table 1 should be interpreted with caution as they do not compare carriers to non-carriers directly. However, both show different cerebral blood flow trajectories in carriers and non-carriers indicating a similar time window of cerebral blood flow decline in carriers in all regions.

Whilst we did not have sufficient statistical power to identify regions of hypoperfusion in mutation carriers stratified by genetic subgroup in independent voxel-based analyses, the post hoc regions of interest analysis produced some noteworthy results. Firstly, C9orf72 and MAPT mutation carriers showed the observed inverse association between cerebral blood flow and years to age of expected
symptom onset in all six regions identified from the original combined group analysis, whereas GRN mutation carriers only showed this effect in the bilateral anterior cingulate/paracingulate, right anterior insula/orbitofrontal, and right supramarginal/angular gyri. This finding is in line with previous literature demonstrating that GRN mutations lead to asymmetric involvement of the brain (Masellis et al., 2006; Gabryelewicz et al., 2010; Rohrer and Warren, 2011), whereas both MAPT and C9orf72-related frontotemporal dementia tends to present with more symmetrical brain findings (Rohrer and Warren, 2011; Mahoney et al., 2012). Finally, only the C9orf72 mutation carriers showed persistent perfusion deficits after partial volume correction in all regions of interest. This suggests that early presymptomatic perfusion anomalies in C9orf72 mutation carriers are robust and not as significantly influenced by underlying structural changes in the same cortical regions. These regional presymptomatic perfusion deficits are consistent with the known slowly progressive behavioural and neuropsychiatric symptoms that occur over many years in C9orf72 mutation carriers (Khan et al., 2012; Galimberti et al., 2013; Devenney et al., 2014).

Because of the multicentre nature of this study, one of the main strengths is that we were able to acquire the largest ASL sample, to date, of presymptomatic individuals at-risk for genetic frontotemporal dementia. However, one drawback of multicentre ASL studies is variability from MRI vendor and/or sequence acquisition procedures (Alsop et al., 2015). We attempted to mitigate nuisance effects through the use of a robust ASL software package (Mutsaerts et al., 2018), which included partial volume error correction (Mutsaerts et al., 2014), intensity normalization, and semi-automatic quality control (Mutsaerts et al., 2017). This has allowed GENFI to overcome the current status quo in ASL imaging studies of neurodegenerative diseases that restricts analyses to those scanned on the same MRI platform, such as what is done in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and Parkinson’s Progression Marker Initiative (PPMI); this significantly limits ASL sample sizes to only a subset of participants in those studies. Another strength is that we included Family as a random factor in our linear mixed-effect models to account for effects of both unknown genomic or environmental influences that may co-vary with cerebral perfusion changes in the participants. Limitations include the relatively small sample size of the genetic subgroups, which reduced power in subgroup analyses. However, through our use of a voxel-based analysis in the entire cohort to identify regions of interest with subsequent post hoc analysis restricted to these regions, we have been able to detect some genetic subgroup differences. Another challenge of using the ASL MRI technique is that physiological perfusion fluctuations are high on both an intra- and interindividual basis. For example, diurnal effects, drug effects, and post-prandial state have been shown to influence perfusion (Clement et al., 2017). This may limit the discovery of small neurovascular coupling-related effects to studies with large sample sizes.

Cerebral blood flow was inversely associated with an individual’s expected age of symptom onset in presymptomatic mutation carriers compared to non-carriers, in signature regions previously implicated in symptomatic frontotemporal dementia. The regional analyses that applied partial volume correction suggest that these effects were most significant in C9orf72 hexanucleotide repeat expansion carriers. These results make ASL MRI promising as a non-invasive imaging biomarker for the presymptomatic stages of genetic frontotemporal dementia. Future work will focus on longitudinal analysis, as well as attempting to identify other factors that lead to phenocconversion to symptomatic frontotemporal dementia. Therapeutic strategies that can preserve or improve cerebral blood flow may hold promise in preventing or delaying symptom onset, respectively, in at-risk presymptomatic mutation carriers, or potentially reversing symptoms in early symptomatic stages of frontotemporal dementia.

**Acknowledgements**

The authors wish to express their gratitude to the participants and their families for taking part in the GENFI study.

**Funding**

This work was funded by the UK Medical Research Council, the Italian Ministry of Health and the Canadian Institutes of Health Research as part of a Centres of Excellence in Neurodegeneration grant, and also a Canadian Institutes of Health Research operating grant (MOP 327387) and funding from the Weston Brain Institute to M.M. J.D.R. is supported by an MRC Clinician Scientist Fellowship (MR/M008525/1) and has received funding from the NIHR Rare Disease Translational Research Collaboration (BRC149/NS/MH). This work was also supported by the MRC UK GENFI grant (MR/M023664/1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests**

The authors report no competing interests.

**Supplementary material**

Supplementary material is available at *Brain* online.

**Appendix I**

**GENFI consortium**

Full details are available in the Supplementary material. Christin Andersson, Silvana Archetti, Andrea Arighi,
References


Wen JD, Rohrer JD, Rossor MN. Clinical review. Frontotemporal dementia. BMJ 2013; 347: g827.